Global Regulatory Intelligence
Log in |  Register

Login to your account

Username *
Password *
Remember Me

Create an account

Registering to our Regulatory Updates easy andis should only
take few minutes. To begin, enter your email enter your email
address below so we can check to see if it is already existing
in our records. Your email address will also be used as your
user name when you log in.

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha

USA: FDA Offers Recommendations on Highlights Section of Labeling

Monday, January 22, 2018: The US Food and Drug Administration (FDA) issued draft guidance providing recommendations on completing certain portions of the Highlights section of labeling for prescription drugs and biologics.

Specifically, the guidance details the content and format of the Product Title and Initial US Approval subsections within the Highlights of Prescribing Information for newly approved drugs and drugs with labels being revised.

In 2006, FDA's final rule on the content and formatting of labeling for human drugs and biologics, also known as the physician labeling rule (PLR), required prescription labeling to contain three sections: Highlights of Prescribing Information, a Table of Contents and Full Prescribing Information.

The Highlights section was developed specifically with physicians and healthcare providers in mind and contains the most important and commonly referenced information within the labeling.

While FDA's guidance on the PLR describes the requirements for what should be included in the Highlights section, the new draft guidance provides greater detail and examples for each specific item in the Product Title and Initial US Approval subsections.

As such, FDA says the new guidance will "bring greater consistency to the presentation of these required elements in labeling and to help ensure these elements provide clear and useful information to the reader."

The guidance also includes recommendations for products with special nomenclature considerations, what not to include in the product title section, and discusses implications for container and carton labeling.

More Details
© 2016 MakroCare. All Rights Reserved.
  Privacy policy